Ann: Pharmaceutical Clinical Study Commences, page-39

Fire empire, OBJ remains a solid investment, the breadth of our IP is robust and there is finally momentum behind commercialising products, the start of the revenue is finally upon us.

The only concern at the moment is the board of directors, their communication, ignorance and their greed, I honestly believe that someone has to go and fresh blood to to take that persons place with a more business orientated mindset.

If anyone doesn't find todays withdrawal of milestone 2 disturbing then I really don't know what would constitute as a red flag. Management deserve a reward but only when the numbers are on the board until then they can continue to grind away on a rather generous salary.